Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story

Abstract

A number of treatment options have been evaluated in order to prevent the severe progression of COVID-19 pneumonia eventually in patients with increased risk due to comorbidities. Remdesivir for a 3-day outpatient course has been associated with a significant lower risk of hospitalization or death. A matched-pair retrospective study was conducted in Department of Infectious Diseases of University General Hospital of Alexandroupolis in order to evaluate the role of remdesivir and vaccination in preventing severe clinical outcome. Nonhospitalized vaccinated patients with a 3-day course of remdesivir had a 75% lower possibility of hospitalization and 95% of respiratory failure. Nobody was intubated or died and the duration of hospital stay was limited (4 day s vs. 10 days). Vaccination and a 3-day course of remdesivir in high risk nonhospitalized patients prevented significantly severe clinical progress of COVID-19 pneumonia.

Keywords:

• COVID-19
• SARS-CoV-2
• remdesivir
• outpatient treatment
• antiviral agent

Disclosure statement

PP has been an advisory board member of GS, MSD, JANSSEN; received honoraria as a speaker for GS, JANSSEN, MSD.

Funding

None.